New combo therapy for advanced cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new combination therapy for people with advanced solid tumors. The goal is to see if it helps shrink tumors or slows their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are able to care for yourself and do light daily activities (ECOG score 0 or 1).
- You have advanced cancer that has been confirmed by a biopsy.
- At least one tumor can be measured on scans (like CT or MRI).
- You have not had a treatment that targets 4-1BB before.
- You have not had another cancer in the last 3 years (except some skin cancers or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new combination of drugs (QLC5513 and QL1706) for people with advanced or metastatic solid tumors that cannot be removed by surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
This early-stage trial tests QLC5508, an experimental cancer medication, in patients with advanced solid tumors that haven't responded to standard treatments. The study focuses on safety, how the drug moves through your body, and potential interactions with other medications.
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.